Publication date: November 2026 Source: Biomedicine & Pharmacotherapy, Volume 204 Author(s): Hyun-Ji Cho, Sung Jin Ryu, Byung Ju Kim, Jeong-A Hwang, Ahyeon Yun, Eok-Cheon Kim, Jae-Ryong Kim, Tae Jun Park, Sung Bae Lee, Young Zoon Kim, Yun-Il Lee, Sang Chul Park, Young-Sam Lee
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...